Stockreport

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

Protara Therapeutics, Inc.  (TARA) 
PDF Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBCPreliminary data from six-month evaluable patient [Read more]